Article Text

Multiplexed endoscopic imaging of Barrett’s neoplasia using targeted fluorescent heptapeptides in a phase 1 proof-of-concept study
  1. Jing Chen1,
  2. Yang Jiang2,
  3. Tse-Shao Chang3,
  4. Bishnu Joshi1,
  5. Juan Zhou1,
  6. Joel H Rubenstein1,
  7. Erik J Wamsteker1,
  8. Richard S Kwon1,
  9. Henry Appelman4,
  10. David G Beer5,
  11. Danielle K Turgeon1,
  12. Eric J Seibel6,
  13. Thomas D Wang1,3,7
  1. 1 Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
  2. 2 Biomedical Engineering, University of Washington, Seattle, WA, USA
  3. 3 Mechanical Engineering, University of Michigan, Ann Arbor, Michigan, USA
  4. 4 Pathology, University of Michigan, Ann Arbor, Michigan, USA
  5. 5 Thoracic Surgery, University of Michigan, Ann Arbor, Michigan, USA
  6. 6 Mechanical Engineering, University of Washington, Seattle, WA, USA
  7. 7 Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA
  1. Correspondence to Dr Thomas D Wang, Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA; thomaswa{at}umich.edu

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Message

Improved methods for early cancer detection arising from Barrett’s oesophagus (BE) are still needed. Imaging molecular expression patterns in BE patients can target neoplasia. We demonstrate a multiplexed fluorescence imaging approach to detect premalignant lesions with two fluorescently labeled heptapeptides specific for EGFR and ErbB2. Twenty-two BE patients underwent endoscopic imaging with a multimodal scanning fiber endoscope (mmSFE). In this pilot study, 92% of neoplastic lesions could be imaged by comparison with pathology, with only 11% false positives. This first-in-human study demonstrates feasibility to concurrently detect multiple targets in vivo and potential for early detection of cancers that are molecularly heterogeneous.

Iniedmore detail

Background

Oesophageal adenocarcinoma (EAC) is a deadly disease that has increased dramatically in incidence over the past several decades.1 2 Endoscopic screening with white light illumination and random biopsy is limited by sampling error.3 Dysplasia often presents with flat architecture and patchy distribution.4 EGFR and ErbB2 are transmembrane tyrosine kinase receptors that stimulate epithelial cell growth, proliferation and differentiation.5 Overexpression of these targets reflects a higher risk for cancer progression.6–8 Multiplexed imaging methods take advantage of the broad spectrum of light over the visible and near-infrared (NIR) regimen. We aim to demonstrate clinical feasibility to visualise EGFR and ErbB2 expression simultaneously in vivo to detect Barrett’s neoplasia.

Methods

Consecutive patients referred for either evaluation or therapy of Barrett’s neoplasia were recruited for the study (NCT03589443). An mmSFE was designed to collect multiplexed fluorescence images concurrently. Target/background (T/B) ratios were calculated for each fluorescence image. More details on the methods and the multiplexed imaging technology can be found in the online supplemental file.

Supplemental material

[gutjnl-2020-322945supp001.pdf]

Results

The peptide QRHKPRE specific for EGFR was labelled with Cy5 via a GGGSK linker, (figure 1A).9 KSPNPRF, specific for ErbB2, was labelled with IRDye800 via a GGGSC linker (figure 1B). …

View Full Text

Supplementary materials